EROGRAN

This brand name is authorized in Nigeria. It is also authorized in Hong Kong SAR China, Singapore.

Active ingredients

The drug EROGRAN contains one active pharmaceutical ingredient (API):

1	Erythromycin UNII 1014KSJ86F - ERYTHROMYCIN ETHYLSUCCINATE
	Erythromycin exerts its antimicrobial action by binding to the 50S ribosomal sub-unit of susceptible microorganisms and suppresses protein synthesis. Erythromycin is bacteriostatic and bactericidal depending on its concentration and the type of organism.
	Read more about Erythromycin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
04-4108	Granules	Erogran Granules GRAN 200 mg/5 mL 100 mL	Granules for Oral Suspension	03/08/2021

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01FA01	Erythromycin	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01F Macrolides, lincosamides and streptogramins → J01FA Macrolides
Discover more medicines within J01FA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
HK	Department of Health Drug Office	38123
NG	Registered Drug Product Database	04-4108
SG	Health Sciences Authority	08042P